Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Daiichi Sankyo Ltd ADR (DSNKY)

Daiichi Sankyo Ltd ADR (DSNKY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 5.73
  • Price/Book 1.14
Trade DSNKY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.9300 +12.60%
on 05/08/24
37.2500 -0.46%
on 06/07/24
+2.7180 (+7.91%)
since 05/07/24
3-Month
28.7500 +28.97%
on 04/17/24
37.2500 -0.46%
on 06/07/24
+4.2100 (+12.81%)
since 03/07/24
52-Week
23.7200 +56.32%
on 10/19/23
37.5662 -1.29%
on 06/13/23
+3.0300 (+8.90%)
since 06/07/23

Most Recent Stories

More News
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 80.02 (-1.00%)
DSNKY : 37.0800 (+0.32%)
MS : 97.14 (+0.30%)
PFE : 28.58 (-0.76%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.58 (-0.76%)
ABBV : 169.42 (+0.50%)
JNJ : 147.08 (+0.45%)
RHHBY : 33.5500 (+0.21%)
GMAB : 27.77 (-2.73%)
AZN : 80.02 (-1.00%)
DSNKY : 37.0800 (+0.32%)
MRK : 130.67 (+0.11%)
LLY : 849.99 (+1.52%)
NVO : 142.88 (+0.34%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 80.02 (-1.00%)
ONCY : 1.0500 (-0.94%)
ONC.TO : 1.44 (unch)
DSNKY : 37.0800 (+0.32%)
GILD : 64.70 (+1.33%)
ARAY : 1.7800 (-1.66%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 80.02 (-1.00%)
ONCY : 1.0500 (-0.94%)
ONC.TO : 1.44 (unch)
DSNKY : 37.0800 (+0.32%)
GILD : 64.70 (+1.33%)
ARAY : 1.7800 (-1.66%)
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

In due time, its new partnership with Daiichi Sankyo could be massive.

MRK : 130.67 (+0.11%)
DSNKY : 37.0800 (+0.32%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

PFE : 28.58 (-0.76%)
DSNKY : 37.0800 (+0.32%)
GILD : 64.70 (+1.33%)
AZN : 80.02 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Daiichi Sankyo Co Ltd was founded on September 28, 2005. The Company is engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the...

See More

Key Turning Points

3rd Resistance Point 37.4967
2nd Resistance Point 37.3733
1st Resistance Point 37.2267
Last Price 37.0800
1st Support Level 36.9567
2nd Support Level 36.8333
3rd Support Level 36.6867

See More

52-Week High 37.5662
Last Price 37.0800
Fibonacci 61.8% 32.2770
Fibonacci 50% 30.6431
Fibonacci 38.2% 29.0092
52-Week Low 23.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar